Loading...
XNASDXCM
Market cap32bUSD
Jan 21, Last price  
86.32USD
1D
-0.54%
1Q
16.58%
Jan 2017
465.36%
IPO
3,192.88%
Name

Dexcom Inc

Chart & Performance

D1W1MN
XNAS:DXCM chart
P/E
62.26
P/S
9.31
EPS
1.39
Div Yield, %
—
Shrs. gr., 5y
3.82%
Rev. gr., 5y
28.56%
Revenues
3.62b
+24.49%
002,169,7904,627,0009,838,00029,693,00048,631,00076,266,00099,900,000160,000,000259,200,000402,000,000573,300,000718,500,0001,031,600,0001,476,000,0001,926,700,0002,448,500,0002,909,800,0003,622,300,000
Net income
542m
+58.70%
-13,946,464-30,767,430-46,599,291-45,878,000-55,184,000-53,524,000-55,170,000-44,746,000-54,500,000-29,800,000-22,400,000-57,600,000-65,600,000-50,200,000-127,100,000101,100,000493,600,000154,700,000341,200,000541,500,000
CFO
749m
+11.80%
-12,428,621-22,553,785-43,734,840-33,207,000-37,451,000-39,389,000-42,676,000-30,126,000-33,100,0002,400,00023,600,00049,000,00056,200,00092,000,000123,200,000314,500,000475,600,000442,500,000669,500,000748,500,000
Earnings
Feb 06, 2025

Profile

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
URL
https://www.dexcom.com/
IPO date
Apr 14, 2005
Employees
7,500
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
3,622,300
24.49%
2,909,800
18.84%
Cost of revenue
3,024,600
2,511,100
Unusual Expense (Income)
NOPBT
597,700
398,700
NOPBT Margin
16.50%
13.70%
Operating Taxes
168,900
49,600
Tax Rate
28.26%
12.44%
NOPAT
428,800
349,100
Net income
541,500
58.70%
341,200
120.56%
Dividends
Dividend yield
Proceeds from repurchase of equity
(662,100)
(535,200)
BB yield
1.25%
1.11%
Debt
Debt current
21,100
793,100
Long-term debt
2,732,700
1,407,400
Deferred revenue
7,400
19,000
Other long-term liabilities
59,600
104,400
Net debt
(8,800)
(274,700)
Cash flow
Cash from operating activities
748,500
669,500
CAPEX
(236,600)
(364,800)
Cash from investing activities
(507,200)
(521,500)
Cash from financing activities
(318,600)
(552,500)
FCF
329,300
189,900
Balance
Cash
2,724,100
2,456,200
Long term investments
38,500
19,000
Excess cash
2,581,485
2,329,710
Stockholders' equity
1,005,100
468,700
Invested Capital
3,724,500
3,827,100
ROIC
11.36%
8.74%
ROCE
12.64%
9.27%
EV
Common stock shares outstanding
425,500
427,500
Price
124.09
9.58%
113.24
-15.64%
Market cap
52,800,295
9.07%
48,410,100
-15.90%
EV
52,791,495
48,135,400
EBITDA
783,700
554,600
EV/EBITDA
67.36
86.79
Interest
20,300
18,600
Interest/NOPBT
3.40%
4.67%